Thorac Cardiovasc Surg 2008; 56(8): 476-481
DOI: 10.1055/s-2008-1038963
Original Thoracic

© Georg Thieme Verlag KG Stuttgart · New York

Pulmonary Resection of Non-Small Cell Lung Cancer: Is Survival in the Elderly Not Affected by Tumor Stage after Complete Resection?

S. Bölükbas1 , S. Beqiri1 , T. Bergmann1 , S. Trainer1 , A. Fisseler-Eckhoff2 , J. Schirren1
  • 1Thoracic Surgery, Kerckhoff Klinik, Bad Nauheim, Germany
  • 2Institute for Pathology and Cytology, Dr.-Horst-Schmidt-Kliniken GmbH, Wiesbaden, Germany
Further Information

Publication History

received January 5, 2008

Publication Date:
14 November 2008 (online)

Abstract

Background: Lung cancer is a disease of the elderly. The aim of this study was to investigate the influence of age on the surgical treatment of non-small cell lung cancer. Methods: We retrospectively reviewed our prospective database of patients older than 75 years of age undergoing pulmonary resection in anatomic units with systematic lymph node dissection for non-small cell lung cancer. Patients were classified as follows: group I (age 75–79 years) and group II (age > 80 years). Morbidity, mortality and survival were analyzed in the overall collective and within both groups, respectively. Results: Between January 1999 and December 2004, 157 patients (group I: 110, group II: 47) were enrolled in this study. 104 lobectomies, 8 bilobectomies, 11 pneumonectomies, 15 sleeve resections and 19 segmentectomies were performed. For all resections mortality and morbidity were 3.8 % and 38.2 %, respectively. There were no significant differences in both groups. The overall 1-year and 5-year survival rates were 83 % and 41 %. Long-term survival was not affected by tumor stage (p = 0.234) in the present study. Conclusions: Even extended pulmonary resections for non-small cell lung cancer are feasible in the elderly. Long-term survival is obtainable. Tumor stage does not seem to play a role with regard to survival provided that complete resection of the tumor in anatomic units with systematic, extensive lymph node dissection is performed. Further investigations are necessary to prove this hypothesis in larger series.

References

  • 1 Reis L AG, Eisner M P, Kosary C L. SEER cancer statistics review, 1973–1998. Bethesda, MD; National Cancer Institute 2001
  • 2 Korst R J, Ginsberg R J. Appropriate surgical treatment of resectable non-small-cell lung cancer.  World J Surg. 2001;  25 184-188
  • 3 Sienel W, Stremmel C, Kirschbaum A, Hinterberger L, Stoelben E, Hasse J, Passlick B. Frequency of local recurrence following segmentectomy of stage IA non-small cell lung cancer is influenced by segment localisation and width of resection margins – implications for patient selection for segmentectomy.  Eur J Cardiothorac Surg. 2007;  31 522-527
  • 4 Cerfolio R J, Bryant A S, Ohja B, Bartolucci A A. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival.  J Thorac Cardiovasc Surg. 2005;  130 151-159
  • 5 Herth F J, Rabe K F, Gasparini S, Annema J T. Transbronchial and transoesophageal (ultrasound-guided) needle aspirations for the analysis of mediastinal lesions.  Eur Respir J. 2006;  28 1264-1275
  • 6 Travis W D, Brambilla E, Müller-Hermelink H, Harris C, eds. Pathology and genetics of tumours of the lung, pleura, thymus, and heart: WHO classification of tumours. New York; Oxford University Press USA 2004: 59-62
  • 7 Mountain C F. Revisions in the international systems for staging lung cancer.  Chest. 1997;  111 1710-1717
  • 8 Dominguez-Ventura A, Allen M S, Cassivi S D, Nichols I IIFC, Deschamps C, Pairolero P C. Lung cancer in octogenarians: factors affecting morbidity and mortality after pulmonary resection.  Ann Thorac Surg. 2006;  82 1175-1179
  • 9 Pagni S, Federico J A, Ponn R B. Pulmonary resection for lung cancer in octogenarians.  Ann Thorac Surg. 1997;  63 785-789
  • 10 Aoki T, Yamato Y, Tsuchida M, Watanabe T, Hayashi J, Hirino T. Pulmonary complications after surgical treatment of lung cancer in octogenarians.  Eur J Cardiothorac Surg. 2000;  18 662-665
  • 11 Port J L, Kent M, Korst R J, Lee P C, Levin M A, Fieder D, Altorki N K. Surgical resection for lung cancer in the octogenarian.  Chest. 2004;  126 733-738
  • 12 Brock M, Kim M P, Hooker C M, Alberg A J, Jordan M M, Poig C M, Xu L, Yang S C. Pulmonary resection in octogenarians with stage I non-small cell lung cancer: a 22-year experience.  Ann Thorac Surg. 2004;  77 271-277
  • 13 Matsuoka H, Okadab M, Sakamotob T, Tsubotab N. Complications and outcomes after pulmonary resection for cancer in patients 80 to 89 years of age.  Eur J Cardiothorac Surg. 2005;  28 380-383
  • 14 Landreneau R J, Sugarbaker D J, Mack M J, Hazelrigg S R, Luketich J D, Fetterman L, Liptay M J, Bartley S, Boley T M, Keenan R J, Ferson P F, Weyant R J, Naunheim K S. Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small cell lung cancer.  J Thorac Cardiovasc Surg. 1997;  113 691-698
  • 15 Dienemann H, Trainer C, Hoffmann H, Bulzebruck H, Muley T, Kayser K, Vogt-Moykopf I. Incomplete resections in bronchial carcinoma: morbidity and prognosis.  Chirurg. 1997;  68 1014-1019
  • 16 Schirren J, Bergmann T, Beqiri S, Bölükbas S, Fisseler-Eckhoff A, Vogt-Moykopf I. Lymphatic spread in resectable lung cancer: can we trust a sentinel lymph node?.  Thorac Cardiov Surg. 2006;  54 372-380
  • 17 Keller S M, Adak S, Wagner H, Johnson D H. Mediastinal lymph node dissection improves survival in patients with stages II and III a non-small cell lung cancer. Eastern Cooperative Oncology Group.  Ann Thorac Surg. 2000;  70 358-365 365-366
  • 18 Kirsh M M, Rotman H, Bove E, Argenta L, Cimmino V, Tashian J, Ferguson P, Sloan H. Major pulmonary resection for bronchogenic carcinoma in the elderly.  Ann Thorac Surg. 1976;  22 369-373
  • 19 Chen Y M, Perng R P, Tsai C M, Whang-Peng J. A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly.  J Thorac Oncol. 2006;  1 141-145
  • 20 Ferrigno D, Buccheri G. Cuneo Lung Cancer Study Group . Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC).  Lung Cancer. 2004;  45 373-380
  • 21 Veronesi A, Crivellari D, Magri M D, Cartei G, Mansutti M, Foladore S, Monfardini S. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients.  Eur J Cancer. 1996;  32 A 1809-1811
  • 22 Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas G M, Von Pawel J. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the Tarceva Lung Cancer Investigation Trial.  J Clin Oncol. 2007;  25 1545-1552
  • 23 Hayakawa K, Mitsuhashi N, Katano S, Saito Y, Nakayama Y, Sakurai H, Akimoto T, Hasegawa M, Yamakawa M, Niibe H. High-dose radiation therapy for elderly patients with inoperable or unresectable non-small cell lung cancer.  Lung Cancer. 2001;  32 81-88
  • 24 Ardizzoni A, Scolaro T, Mereu C, Cafferata M A, Tixi L, Baciqalupo A, Tiseo M, Monetti F, Rosso R. Induction chemotherapy with carboplatin-paclitaxel followed by standard radiotherapy with concurrent daily low-dose cisplatin plus weekly paclitaxel for inoperable non-small-cell lung cancer.  Am J Clin Oncol. 2005;  28 58-64

Dr. MD, PhD Servet Bölükbas

Kerckhoff Klinik
Thoracic Surgery

Beneckestraße 2–8

61321 Bad Nauheim

Germany

Phone: + 49 (0) 6 03 29 96 24 02

Fax: + 49 (0) 6 03 29 96 24 17

Email: servet_boeluekbas@web.de

    >